Jade Biosciences 簽署抗體全球獨家許可協議，最高里程碑款項達2,200萬美元

8-K

 NASDAQ false 0001798749 0001798749 2026-06-29 2026-06-29 
  
  
 UNITED STATES
 SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549
  
  

 FORM 8-K
  
  

 CURRENT REPORT
 Pursuant to Section 13 or 15(d)
 of the Securities Exchange Act of 1934
 Date of Report (Date of earliest event reported): June 29, 2026
  
  

 Jade Biosciences, Inc.
 (Exact name of registrant as specified in its charter)
  
  

  

Nevada
 
001-40544
 
83-1377888

 (State or other jurisdiction
 of incorporation)

 
 (Commission
 File Number)

 
 (IRS Employer
 Identification No.)

  

 221 Crescent St., Building 23
 Suite 105
 Waltham, MA

 
02453

(Address of principal executive offices)
 
(Zip Code)
 (Registrant’s telephone number, including area code): (781) 312-3013
 N/A
 (Former name or former address, if changed since last report)
  
  

 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
  

☐
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

  

☐
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

  

☐
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  

☐
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 Securities registered pursuant to Section 12(b) of the Act:
  

 Title of each class

 
 Trading
 Symbol(s)

 
 Name of each exchange
on which registered

Common stock, par value $0.0001 per share
 
JBIO
 
 The Nasdaq Capital Market 
 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 Emerging growth company ☒
 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
  
  
  

 

Item 1.01.
 Entry into a Material Definitive Agreement. 

 On June 29, 2026, Jade Biosciences, Inc. (the “Company”) entered into a License Agreement (the “JADE301 License Agreement”) with Paragon Therapeutics, Inc. (“Paragon”), pursuant to which Paragon granted the Company a royalty-bearing, worldwide, exclusive and sublicensable license to use, make, sell, import, export and otherwise exploit certain monospecific antibodies and products targeting an undisclosed target (the “Target”) in the field of prophylaxis, palliation, treatment and diagnosis of human disease and disorders in all therapeutic areas (the “Field”). 
 Under the terms of the JADE301 License Agreement, the Company is obligated to pay Paragon up to $22.0 million based on specific development and regulatory milestones, including a $1.5 million fee for nomination of a development candidate, which was paid in January 2026, and a further milestone payment of $2.5 million upon the first dosing of a human patient in a Phase 1 trial. On a product-by-product basis, the Company is obligated to pay sublicensing fees of up to approximately $20.1 million, mainly upon the achievement of commercial milestones. The Company will pay Paragon a low to mid-single-digit percentage royalty based on annual net sales of monospecific products in the Field and in the territory, and a mid-single-digit percentage royalty based on annual net sales of multispecific products in the Field and in the territory, subject to a 30% reduction if there is no valid patent covering the product in the country of sale. On a country-by-country basis, the royalty term for a product ends on the later of (i) the twelfth anniversary of the date of first sale of a Company product or (ii) the expiration of the last-to-expire valid patent covering the product in the country at issue. 
 Paragon will not conduct any new campaigns that generate monospecific antibodies targeting the Target in the Field for at least five years. The JADE301 License Agreement may be terminated on 60 days’ notice by us; on material breach without cure; and to the extent permitted by law, on a party’s insolvency or bankruptcy. 
 The foregoing is a summary description of certain terms of the JADE301 License Agreement, does not purport to be complete and is qualified in its entirety by reference to the full text of the JADE301 License Agreement to be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending June 30, 2026. 

 

 SIGNATURE 
 Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 
  

 

 
Jade Biosciences, Inc.

Date: July 1, 2026
 

 
By:
 
 /s/ Bradford Dahms

 

 
Name:
 
Bradford Dahms

 

 
Title:
 
Chief Financial Officer and Treasurer